ArticleBMC medical imaging2026
Predicting STAS in peripheral stage I lung adenocarcinoma: the incremental value of CT-based tumor disappearance rate, with a focus on part-solid nodules.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTumor spread through air spaces (STAS) is a critical prognostic factor in peripheral stage I lung adenocarcinoma (LUAD) and substantially influences surgical decision-making. However, accurate preoperative prediction of STAS remains challenging. This study aimed to investigate the value of computed tomography (CT)-derived tumor disappearance rate (TDR) as a novel imaging biomarker for STAS prediction, and to evaluate the incremental benefit of combining TDR with consolidation tumor ratio (CTR) in part-solid nodules.
methodsThis retrospective study enrolled 244 patients with peripheral stage I LUAD who underwent surgical resection at Xuzhou Hospital Affiliated to Jiangsu University between January 2022 and December 2023. The multivariate generalized additive model (GAM) was employed to characterize the adjusted dose-response relationship between TDR and STAS, with threshold effect analysis performed via the log-likelihood ratio test. The predictive performance of TDR, CTR, and the combined TDR-CTR index (COM) was compared using ROC curves, DeLong test, and bootstrap resampling validation.
resultsSTAS was identified in 51 (20.9%) patients. The STAS-positive group exhibited a significantly lower TDR compared with the STAS-negative group (0.26 +/- 0.32 vs. 0.51 +/- 0.44, P < 0.001). Multivariate analysis identified TDR and spiculation sign as independent risk factors for STAS. TDR demonstrated a non-linear association with STAS (P < 0.001), with a threshold value of 0.610. In the part-solid nodule subgroup, the combined TDR-CTR index achieved an AUC of 0.793 (95% CI: 0.654-0.932), significantly outperforming CTR alone (AUC = 0.525, P = 0.040). Bootstrap validation confirmed favorable stability. While promising in this exploratory subgroup analysis, further validation in larger cohorts is warranted due to the wide confidence interval of the combined TDR-CTR index.
conclusionsCT-derived TDR is a valuable biomarker for preoperative STAS risk stratification in peripheral stage I LUAD. The combined TDR-CTR index significantly enhances STAS prediction in part-solid nodules, addressing the limitations of CTR alone and supporting individualized surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.